Stock Ratings / Health Care / BYSI / insiders

TXMD (48) AYTU (41) QNTM (58) ACTU (43) ⌘ Pro Terminal →

BeyondSpring Inc. (BYSI) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.52 -1.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.52

BeyondSpring Inc. (BYSI) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $21.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.52 (-0.46%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BYSI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY BYSI SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.61-8.2% Next Q

Q2 (-2Q)

Grade D$0.56-23.2% Next Q

Q3 (-1Q)

Grade D$0.43+20.9% Next Q

Current

Grade D-$0.52-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BYSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BYSI currently carries a cautious 42/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.55) forces dealer call-delta covering toward $2.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BYSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BYSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BYSI Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BYSI)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BYSI. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BYSI)

✓Walkthrough of BYSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BYSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -65.79%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.50H $0.68L $0.50C $0.52VOL 217.9K

RES: $0.98SUP: $0.40SMA50: $0.66SMA200: $1.27

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BYSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BYSI Butterfly Map → + Track BYSI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BYSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BYSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BYSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BYSI)

Health Care Rank #591 of 1016 ⚔️ TXMD vs BYSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BYSI vs. TXMD, AYTU, QNTM, ACTU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BeyondSpring Inc. (BYSI) ranks #591 by composite RQD confidence (42/100, grade D-) and #827 by equity capitalization ($21.2M). Within this direct 5-issuer industry benchmark cohort, BYSI leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with BYSI at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BYSI ACTIVE BeyondSpring Inc.	D-	42/100	—	—	-35.0%	-1.49%	$21.2M	Benchmark Subject
TXMD TherapeuticsMD Inc.	D	48/100	—	—	-12.9%	+2.24%	$21.2M	/txmd-vs-bysi →
AYTU Aytu BioPharma Inc.	D-	41/100	—	69.0%	-35.0%	+0.51%	$21.5M	/aytu-vs-bysi →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D+	58/100	—	—	—	+2.95%	$20.7M	/qntm-vs-bysi →
ACTU Actuate Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.21%	$20.4M	/actu-vs-bysi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001677940

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BeyondSpring Inc. (BYSI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.0M, operating cash flow of -$19.8M, and free cash flow of -$19.8M (-18.9% YoY). On the balance sheet, BYSI closed FY2025 with $25.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$1.0M	-$19.8M	-$19.8M	$25.9M	—
FY2024 (FY)	2024-12-31	$0	-$11.1M	-$16.4M	-$16.7M	$34.3M	—
FY2023 (FY)	2023-12-31	$0	-$21.0M	-$16.5M	-$16.5M	—	—

3. BYSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.52 (-1.49% 1D, market cap $21.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BYSI ranks #591 in composite RQD confidence.

How does BYSI compare to TXMD and AYTU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TXMD (TherapeuticsMD Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -12.9%, cap $21.2M) and AYTU (Aytu BioPharma Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $21.5M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BYSI?

Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $0 in revenue, -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BYSI trading relative to its 50-day, 200-day, and 52-week technical levels?

BYSI last traded at $0.52 (-1.49% on volume of 31,106 shares), positioning the stock -21.21% below its 50-day simple moving average ($0.66) and -59.06% below its 200-day simple moving average ($1.27). Across its 52-week range of $0.42 to $2.44, BYSI sits at the 5.0% percentile with a 14-day RSI of 54.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.59).

BYSI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are BYSI insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BYSI leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: BYSI RQD Cockpit BYSI 12M Forecast BYSI Earnings & Move BYSI Dividends & DRIP BYSI Insiders & 13F BYSI Whale Options BYSI Profit Sankey BYSI News & Why